sorafenib has been researched along with plx4032 in 37 studies
Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (plx4032) | Trials (plx4032) | Recent Studies (post-2010) (plx4032) |
---|---|---|---|---|---|
6,520 | 730 | 5,251 | 1,657 | 103 | 1,587 |
Protein | Taxonomy | sorafenib (IC50) | plx4032 (IC50) |
---|---|---|---|
Chain A, AKAP9-BRAF fusion protein | Homo sapiens (human) | 0.031 | |
RAF proto-oncogene serine/threonine-protein kinase | Homo sapiens (human) | 0.182 | |
Serine/threonine-protein kinase A-Raf | Homo sapiens (human) | 0.521 | |
Serine/threonine-protein kinase B-raf | Homo sapiens (human) | 0.0897 | |
Serine/threonine-protein kinase B-raf | Mus musculus (house mouse) | 0.03 | |
Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 0.36 | |
Dual specificity mitogen-activated protein kinase kinase 2 | Homo sapiens (human) | 1.5 | |
Dual specificity mitogen-activated protein kinase kinase 1 | Homo sapiens (human) | 1.5 | |
Mitogen-activated protein kinase kinase kinase 20 | Homo sapiens (human) | 0.0272 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 33 (89.19) | 24.3611 |
2020's | 4 (10.81) | 2.80 |
Authors | Studies |
---|---|
Cho, HJ; El-Gamal, MI; Hah, JM; Kim, H; Kim, HJ; Lee, SH; Oh, CH; Sim, T; Yoo, KH | 1 |
Abdel-Maksoud, MS; El-Gamal, MI; Jung, MH; Oh, CH; Sim, T; Yoo, KH | 1 |
Kim, J; Wang, X | 1 |
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
Choi, HS; El-Gamal, MI; Hong, JH; Kim, G; Koh, EJ; Lee, SG; Lee, SH; Oh, CH; Sim, T; Yoo, KH | 1 |
Chen, K; Li, B; Shen, J; Wang, G; Wang, H; Xu, Z; Yang, M; Zeng, B; Zhu, W | 1 |
Bullock, AN; Canning, P; Choi, S; Cuny, GD; Mohedas, AH; Sanvitale, CE; Wang, Y; Xing, X; Yu, PB | 1 |
Chen, Y; Gu, Y; Han, W; Lu, T; Qian, W; Tang, W; Yang, W; Zhang, F; Zhou, X | 1 |
Blagg, BS; Garg, G; Ghosh, S; Hall, JA; Seedarala, S; Zhao, H | 1 |
Chen, Y; Lu, T; Mao, T; Tang, W; Wang, L; Zhang, L; Zhang, Q; Zhang, Z; Zhi, Y; Zhou, X; Zhu, G | 1 |
Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
Agianian, B; Gavathiotis, E | 1 |
Berrios, KN; Estrada, MA; Grasso, M; Marmorstein, R; Winkler, JD | 1 |
Guo, Y; He, J; Li, Y; Liu, M; Liu, Y; Xiao, J; Yu, W; Zhang, Q | 1 |
Abdel-Maksoud, MS; Ali, EMH; Ammar, UM; Mersal, KI; Oh, CH; Yoo, KH | 1 |
Alsaghir, FM; El-Gamal, MI; Sbenati, RM; Semreen, AM; Semreen, MH; Shehata, MK | 1 |
Rosen, N; Solit, D | 1 |
Bedeir, A; Berger, W; Ghassemi, S; Grasl-Kraupp, B; Grusch, M; Heffeter, P; Heinzle, C; Held, G; Holzmann, K; Marian, B; Metzner, T; Micksche, M; Peter-Vörösmarty, B; Pirker, C; Spiegl-Kreinecker, S | 1 |
Ardlie, K; Chalk, CJ; Dziunycz, P; Garraway, LA; Hofbauer, GF; Jones, R; Kamsukom, N; Kee, D; MacConaill, LE; McArthur, GA; Oberholzer, PA; Palescandolo, E; Piris, A; Robert, C; Roden, C; Schadendorf, D; Sucker, A | 1 |
Allegra, M; Bahadoran, P; Ballotti, R; Giacchero, D; Hofman, P; Lacour, JP; Le Duff, F; Long-Mira, E; Passeron, T | 1 |
Allegra, M; Bahadoran, P; Ballotti, R; Bastian, BC; Bollag, G; Botton, T; Burton, EA; Garrido, MC; LeBoit, PE; McCalmont, TH; Nelson, T; Rocchi, S; Sparatta, A; Vemula, SS; Yeh, I | 1 |
Holderfield, M; Nagel, TE; Stuart, DD | 1 |
Anseth, KS; Jones, CE; Leight, JL; Lin, AJ; Tokuda, EY | 1 |
Chen, YC; Chin, SY; Chou, CL; Jiang, MC; Lee, WR; Liu, KH; Shen, SC; Shih, YH; Tseng, JT | 1 |
Nishio, K; Togashi, Y | 1 |
Arora, R; Astorga-Wells, J; Bonnet, P; Brehmer, D; Di Michele, M; Gevaert, K; Jacoby, E; Linders, JT; Martens, L; Stes, E; van Heerde, E; Vandenbussche, J; Vandermarliere, E; Zubarev, R | 1 |
Fiskus, W; Mitsiades, N | 1 |
Amitay-Laish, I; Didkovsky, E; Hendler, D; Hodak, E; Lotem, M; Merims, S; Ollech, A; Popovtzer, A; Stemmer, SM | 1 |
Okano, S | 1 |
Lim, SY; Menzies, AM; Rizos, H | 1 |
Bruno, R; Chatelut, E; Ratain, MJ | 1 |
Fulda, S | 1 |
Avenia, N; Ayroldi, E; Cannarile, L; Cari, L; Marchetti, MC; Moretti, S; Petrillo, MG; Puxeddu, E; Riccardi, C; Ricci, E; Ronchetti, S | 1 |
Moorthy, A; Srivastava, A | 1 |
Franken, MG; Gheorghe, M; Haanen, JBAG; Leeneman, B; Uyl-de Groot, CA; van Baal, PHM | 1 |
Anbar, HS; El-Gamal, MI; Jeon, HR; Kwon, D; Lee, BS; Oh, CH; Tarazi, H | 1 |
Amaria, RN; Call, SG; Falchook, GS; Holley, VR; Hong, DS; Huang, HJ; Janku, F; Kato, S; Meric-Bernstam, F; Naing, A; Patel, SP; Piha-Paul, SA; Sakamuri, D; Tsimberidou, AM; Zinner, RG | 1 |
9 review(s) available for sorafenib and plx4032
Article | Year |
---|---|
Current Insights of BRAF Inhibitors in Cancer.
Topics: Animals; Drug Discovery; Humans; Mutation; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf | 2018 |
The association between anti-tumor potency and structure-activity of protein-kinases inhibitors based on quinazoline molecular skeleton.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Humans; Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Quinazolines | 2019 |
Evaluation of imidazo[2,1-b]thiazole-based anticancer agents in one decade (2011-2020): Current status and future prospects.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Imidazoles; Models, Molecular; Protein Binding; Protein Kinase Inhibitors; Ribosomal Protein S6 Kinases, 90-kDa; Signal Transduction; Structure-Activity Relationship; Thiazoles; Tubulin | 2021 |
Mechanism and consequences of RAF kinase activation by small-molecule inhibitors.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Enzyme Activation; Humans; Indoles; Melanoma; Niacinamide; Phenylurea Compounds; Protein Multimerization; Protein Processing, Post-Translational; raf Kinases; Sorafenib; Sulfonamides; Vemurafenib | 2014 |
[Kinase inhibitors and their resistance].
Topics: Antibodies, Monoclonal, Humanized; Benzamides; Biomarkers, Tumor; Crizotinib; Drug Discovery; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Imatinib Mesylate; Indoles; Molecular Targeted Therapy; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrazoles; Pyridines; Pyrimidines; Quinazolines; Signal Transduction; Sorafenib; Sulfonamides; Trastuzumab; Vemurafenib | 2015 |
[New molecular target therapy for thyroid neoplasms and malignant melanomas].
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Clinical Trials as Topic; Humans; Indoles; Ipilimumab; Melanoma; Molecular Targeted Therapy; Niacinamide; Nivolumab; Phenylurea Compounds; Quinolines; Skin Neoplasms; Sorafenib; Sulfonamides; Thyroid Neoplasms; Vemurafenib | 2015 |
Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; CTLA-4 Antigen; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Immunotherapy; Indoles; Ipilimumab; MAP Kinase Kinase 1; Melanoma; Molecular Targeted Therapy; Niacinamide; Nivolumab; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Pyrimidines; Quinazolines; Signal Transduction; Skin Neoplasms; Sorafenib; Sulfonamides; Vemurafenib | 2017 |
Repurposing anticancer drugs for targeting necroptosis.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Antioxidants; Apoptosis; Drug Repositioning; Humans; Imidazoles; Indazoles; Necrosis; Oximes; Pyridazines; Pyrimidines; Reperfusion Injury; Sorafenib; Sulfonamides; Systemic Inflammatory Response Syndrome; Vemurafenib | 2018 |
A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azetidines; Benzimidazoles; Cancer Vaccines; Carboplatin; Dacarbazine; gp100 Melanoma Antigen; Humans; Hydrazines; Imidazoles; Interleukin-2; Ipilimumab; Lenalidomide; Melanoma; Network Meta-Analysis; Nitrosourea Compounds; Nivolumab; Organophosphorus Compounds; Oximes; Paclitaxel; Piperidines; Progression-Free Survival; Proportional Hazards Models; Pyridones; Pyrimidinones; Skin Neoplasms; Sorafenib; Survival Rate; Temozolomide; Treatment Outcome; Vemurafenib | 2019 |
28 other study(ies) available for sorafenib and plx4032
Article | Year |
---|---|
New diarylureas and diarylamides possessing acet(benz)amidophenyl scaffold: design, synthesis, and antiproliferative activity against melanoma cell line.
Topics: Amides; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Design; Humans; Melanoma; Urea | 2012 |
Design, synthesis, and antiproliferative activity of new 1H-pyrrolo[3,2-c]pyridine derivatives against melanoma cell lines. Part 2.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Drug Design; Drug Screening Assays, Antitumor; Humans; Melanoma; Pyridines; Pyrroles; Structure-Activity Relationship | 2012 |
Conformation-specific effects of Raf kinase inhibitors.
Topics: Dimerization; Models, Molecular; Protein Conformation; Protein Kinase Inhibitors; raf Kinases | 2012 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
New diarylamides and diarylureas possessing 8-amino(acetamido)quinoline scaffold: synthesis, antiproliferative activities against melanoma cell lines, kinase inhibition, and in silico studies.
Topics: Acetamides; Amides; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Computer Simulation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Extracellular Signal-Regulated MAP Kinases; Humans; Melanoma; Mitogen-Activated Protein Kinase Kinases; Molecular Structure; Protein Kinase Inhibitors; Quinolines; Structure-Activity Relationship; Urea | 2013 |
Overman rearrangement and Pomeranz-Fritsch reaction for the synthesis of benzoazepinoisoquinolones to discover novel antitumor agents.
Topics: Antineoplastic Agents; Benzazepines; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; HCT116 Cells; Hep G2 Cells; Humans; Indoles; K562 Cells; Melanoma; Molecular Structure; Niacinamide; Phenylurea Compounds; Quinolones; Sorafenib; Structure-Activity Relationship; Sulfonamides; Vemurafenib | 2013 |
Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.
Topics: Activin Receptors, Type I; Aminopyridines; Humans; Mutation; Myositis Ossificans; Phenols; Protein Kinase Inhibitors; Structure-Activity Relationship | 2014 |
Design, synthesis and biological evaluation of bis-aryl ureas and amides based on 2-amino-3-purinylpyridine scaffold as DFG-out B-Raf kinase inhibitors.
Topics: Amides; Animals; Benzamides; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Structure; Neoplasms, Experimental; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Purines; Structure-Activity Relationship; Urea | 2015 |
Novobiocin Analogues That Inhibit the MAPK Pathway.
Topics: Antineoplastic Agents; Cell Proliferation; Cells, Cultured; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; HSP90 Heat-Shock Proteins; Humans; Mitogen-Activated Protein Kinases; Models, Molecular; Molecular Structure; Novobiocin; Signal Transduction; Structure-Activity Relationship | 2016 |
Design, synthesis and evaluation of derivatives based on pyrimidine scaffold as potent Pan-Raf inhibitors to overcome resistance.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Resistance, Neoplasm; Humans; Melanoma; Protein Kinase Inhibitors; Pyrimidines; raf Kinases; Rats | 2017 |
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |
N-(7-Cyano-6-(4-fluoro-3-(2-(3-(trifluoromethyl)phenyl)acetamido)phenoxy)benzo[d]thiazol-2-yl)cyclopropanecarboxamide (TAK632) Promotes Inhibition of BRAF through the Induction of Inhibited Dimers.
Topics: Benzothiazoles; Cell Line, Tumor; Dimerization; Drug Design; Humans; MAP Kinase Signaling System; Models, Molecular; Nitriles; Protein Kinase Inhibitors; Protein Multimerization; Protein Structure, Quaternary; Proto-Oncogene Proteins B-raf | 2018 |
Design and synthesis of novel pyrrolo[2,3-b]pyridine derivatives targeting
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Humans; Molecular Docking Simulation; Molecular Structure; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridines; Pyrroles; Structure-Activity Relationship | 2020 |
Oncogenic RAF: a brief history of time.
Topics: Benzenesulfonates; Drug Screening Assays, Antitumor; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Humans; Indoles; Melanoma; Mutation; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Pyridines; Sorafenib; Sulfonamides; Time Factors; Vemurafenib | 2010 |
Fibroblast growth factor receptors as therapeutic targets in human melanoma: synergism with BRAF inhibition.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Cell Line, Tumor; Dacarbazine; Drug Screening Assays, Antitumor; Genes, Dominant; Humans; Indoles; Melanocytes; Melanoma; Niacinamide; Phenylurea Compounds; Prognosis; Proto-Oncogene Proteins B-raf; Pyridines; Receptors, Fibroblast Growth Factor; Signal Transduction; Skin Neoplasms; Sorafenib; Sulfonamides; Vemurafenib | 2011 |
RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors.
Topics: Adult; Aged; Aged, 80 and over; Benzenesulfonates; Carcinoma, Squamous Cell; Female; Gene Expression Regulation, Neoplastic; Genotype; Humans; Indoles; Male; Mass Spectrometry; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridines; Skin Neoplasms; Sorafenib; Sulfonamides; Vemurafenib | 2012 |
Major clinical response to a BRAF inhibitor in a patient with a BRAF L597R-mutated melanoma.
Topics: Aged; Antineoplastic Agents; Arginine; Back; Cell Survival; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Imidazoles; Indoles; Leucine; Lung Neoplasms; MAP Kinase Signaling System; Melanoma; Niacinamide; Oximes; Phenylurea Compounds; Point Mutation; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sorafenib; Sulfonamides; Vemurafenib | 2013 |
Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy.
Topics: Adolescent; Adult; Child, Preschool; Enzyme Activation; Female; Gene Rearrangement; Humans; Indoles; Male; MAP Kinase Signaling System; Melanocytes; Melanoma; Middle Aged; Molecular Targeted Therapy; Nevus, Epithelioid and Spindle Cell; Niacinamide; Oncogene Proteins, Fusion; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sorafenib; Sulfonamides; Vemurafenib; Young Adult | 2013 |
Multifunctional bioscaffolds for 3D culture of melanoma cells reveal increased MMP activity and migration with BRAF kinase inhibition.
Topics: Cell Culture Techniques; Cell Line, Tumor; Cell Movement; Collagenases; Humans; Hydrogels; Indoles; Melanoma; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Sorafenib; Sulfonamides; Tissue Scaffolds; Vemurafenib | 2015 |
Early decline in serum phospho-CSE1L levels in vemurafenib/sunitinib-treated melanoma and sorafenib/lapatinib-treated colorectal tumor xenografts.
Topics: Animals; Antibodies, Neoplasm; Cell Line, Tumor; Cell Proliferation; Cellular Apoptosis Susceptibility Protein; Colorectal Neoplasms; Extracellular Signal-Regulated MAP Kinases; Humans; Indoles; Lapatinib; Male; Melanoma; Mice, Inbred NOD; Mice, SCID; Niacinamide; Phenylurea Compounds; Phosphorylation; Pyrroles; Quinazolines; Sorafenib; Sulfonamides; Sunitinib; Vemurafenib; Xenograft Model Antitumor Assays | 2015 |
Limited Proteolysis Combined with Stable Isotope Labeling Reveals Conformational Changes in Protein (Pseudo)kinases upon Binding Small Molecules.
Topics: Adenosine Triphosphate; Adenylyl Imidodiphosphate; Cell Line, Tumor; Cell Survival; Deuterium Exchange Measurement; Humans; Indoles; Isotope Labeling; MAP Kinase Signaling System; Mass Spectrometry; Molecular Dynamics Simulation; Mutation; Niacinamide; Peptides; Phenylurea Compounds; Phosphorylation; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Protein Structure, Secondary; Protein Structure, Tertiary; Proteolysis; Proteomics; Proto-Oncogene Proteins B-raf; Sorafenib; Sulfonamides; Trypsin; Vemurafenib | 2015 |
B-Raf Inhibition in the Clinic: Present and Future.
Topics: Antineoplastic Agents; Colonic Neoplasms; Drug Resistance, Neoplasm; Humans; Imidazoles; Indoles; MAP Kinase Signaling System; Melanoma; Mitogen-Activated Protein Kinase Kinases; Niacinamide; Oximes; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Sorafenib; Sulfonamides; Thyroid Neoplasms; Vemurafenib | 2016 |
Widespread morbilliform rash due to sorafenib or vemurafenib treatment for advanced cancer; experience of a tertiary dermato-oncology clinic.
Topics: Aged; Antineoplastic Agents; Drug Eruptions; Exanthema; Female; Humans; Indoles; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Steroids; Sulfonamides; Vemurafenib | 2016 |
Intraindividual Pharmacokinetic Variability: Focus on Small-Molecule Kinase Inhibitors.
Topics: Drug Monitoring; Enzyme Inhibitors; Food-Drug Interactions; Humans; Indazoles; Indoles; Metabolic Clearance Rate; Phosphotransferases; Pyrimidines; Sorafenib; Sulfonamides; Vemurafenib | 2018 |
Long glucocorticoid-induced leucine zipper regulates human thyroid cancer cell proliferation.
Topics: Butadienes; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cyclic AMP Response Element-Binding Protein; Cyclic AMP-Dependent Protein Kinases; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Mitogen-Activated Protein Kinases; Models, Biological; Nitriles; Phosphorylation; Promoter Regions, Genetic; Protein Kinase Inhibitors; Sorafenib; Thyroid Neoplasms; Transcription Factors; Transcriptional Activation; Up-Regulation; Vemurafenib | 2018 |
Sorafenib induces synergistic effect on inhibition of vemurafenib resistant melanoma growth.
Topics: Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Humans; Indoles; Inhibitory Concentration 50; Melanoma; Mutation; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sorafenib; Sulfonamides; Vemurafenib | 2019 |
Imidazothiazole-based potent inhibitors of V600E-B-RAF kinase with promising anti-melanoma activity: biological and computational studies.
Topics: Antineoplastic Agents; Carbamates; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Imidazoles; Melanoma; Molecular Dynamics Simulation; Oximes; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Quantitative Structure-Activity Relationship; Sorafenib; Sulfonamides; Thiazoles; Vemurafenib | 2020 |
Dose-escalation study of vemurafenib with sorafenib or crizotinib in patients with BRAF-mutated advanced cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell-Free Nucleic Acids; Crizotinib; Female; Humans; Male; Middle Aged; Mutation; Neoplasms; Proto-Oncogene Proteins B-raf; Sorafenib; Vemurafenib | 2021 |